Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)-Reference-Cited by-同舟云学术

Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)

Published:2013-12-17 Issue:3 Volume:55 Page:527-532
ISSN:0449-3060
Container-title:Journal of Radiation Research
language:en
Short-container-title:Journal of Radiation Research

Author:

Aoki M.,Miki K.,Kido M.,Sasaki H.,Nakamura W.,Kijima Y.,Kobayashi M.,Egawa S.,Kanehira C.

Publisher

Oxford University Press (OUP)

Subject

Health, Toxicology and Mutagenesis,Radiology, Nuclear Medicine and imaging,Radiation

Link

http://academic.oup.com/jrr/article-pdf/55/3/527/3098295/rrt134.pdf

Reference21 articles.

1. Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

2. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer

3. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime

4. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

5. Final Report of Multicenter Canadian Phase III Randomized Trial of 3 Versus 8 Months of Neoadjuvant Androgen Deprivation Therapy Before Conventional-Dose Radiotherapy for Clinically Localized Prostate Cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients with PSA below 0.2 ng/mL at 8 years post high‐dose‐rate brachytherapy have an extremely low risk of subsequent recurrence;International Journal of Urology;2023-08-31

2. Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer;Strahlentherapie und Onkologie;2021-04-28

3. Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer;Strahlentherapie und Onkologie;2018-11-02

4. Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now?;Practical Radiation Oncology;2018-05

5. Cancer‐specific mortality of high‐risk prostate cancer after carbon‐ion radiotherapy plus long‐term androgen deprivation therapy;Cancer Science;2017-11-03